Long‐term safety of botulinum toxin type A
Identifieur interne : 004047 ( Main/Exploration ); précédent : 004046; suivant : 004048Long‐term safety of botulinum toxin type A
Auteurs : Markus Naumann [Allemagne] ; A. Peter Moore [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-09.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- therapy : Nervous System Diseases.
- Clinical Trials as Topic, Humans, Time Factors, Treatment Outcome.
Url:
DOI: 10.1002/mds.10495
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004132
- to stream Istex, to step Curation: 004132
- to stream Istex, to step Checkpoint: 002977
- to stream PubMed, to step Corpus: 003687
- to stream PubMed, to step Curation: 003687
- to stream PubMed, to step Checkpoint: 003739
- to stream Ncbi, to step Merge: 000B77
- to stream Ncbi, to step Curation: 000B77
- to stream Ncbi, to step Checkpoint: 000B77
- to stream Main, to step Merge: 005C70
- to stream Main, to step Curation: 004047
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term safety of botulinum toxin type A</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C21BADE2AD5AFC9C2C60103AF192D2D33091F69C</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10495</idno>
<idno type="url">https://api.istex.fr/document/C21BADE2AD5AFC9C2C60103AF192D2D33091F69C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004132</idno>
<idno type="wicri:Area/Istex/Curation">004132</idno>
<idno type="wicri:Area/Istex/Checkpoint">002977</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Naumann M:long:term:safety</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502686</idno>
<idno type="wicri:Area/PubMed/Corpus">003687</idno>
<idno type="wicri:Area/PubMed/Curation">003687</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003739</idno>
<idno type="wicri:Area/Ncbi/Merge">000B77</idno>
<idno type="wicri:Area/Ncbi/Curation">000B77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B77</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Naumann M:long:term:safety</idno>
<idno type="wicri:Area/Main/Merge">005C70</idno>
<idno type="wicri:Area/Main/Curation">004047</idno>
<idno type="wicri:Area/Main/Exploration">004047</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term safety of botulinum toxin type A</title>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology University of Würzburg Würzburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuroscience Liverpool University Liverpool</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1080">1080</biblScope>
<biblScope unit="page" to="1081">1081</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C21BADE2AD5AFC9C2C60103AF192D2D33091F69C</idno>
<idno type="DOI">10.1002/mds.10495</idno>
<idno type="ArticleID">MDS10495</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum Toxins, Type A (adverse effects)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Nervous System Diseases (therapy)</term>
<term>Neuromuscular Agents (adverse effects)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:C21BADE2AD5AFC9C2C60103AF192D2D33091F69C |texte= Long‐term safety of botulinum toxin type A }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |